(Q67696139)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1713814%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

title

In vivo treatment with interferon causes augmentation of IL-2 induced lymphokine-activated killer cells in the organs of mice (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1713814%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

1 reference

https://api.crossref.org/works/10.1111/J.1365-2249.1991.TB05726.X

6 November 2022

R. K. Puri

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1713814

6 November 2022

P. Leland

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1713814

6 November 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1713814

6 November 2022

publication date

1 August 1991

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1713814%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

17 September 2019

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2249.1991.tb05726.x

1 reference

Crossref

https://api.crossref.org/works/10.1111/J.1365-2249.1991.TB05726.X

https://academic.oup.com/cei/article-pdf/85/2/317/42214363/j.1365-2249.1991.tb05726.x.pdf

6 November 2022

file format

Portable Document Format

1 reference

Crossref

https://api.crossref.org/works/10.1111/J.1365-2249.1991.TB05726.X

Clinical and Experimental Immunology

6 November 2022

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1713814%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1713814%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1713814%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

page(s)

317-325

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1713814%20AND%20SRC:MED&resulttype=core&format=json

Natural cell-mediated cytotoxicity in rats. II.In vivo augmentation of NK-cell activity

17 September 2019

cites work

1 reference

12 December 2020

Identification of a cell-surface antigen selectively expressed on the natural killer cell

1 reference

12 December 2020

Enhancement by interferon of the specific cytotoxicity of sensitized lymphocytes

1 reference

12 December 2020

Antigen(s)-specific tumour-infiltrating lymphocytes from tumour induced by human herpes virus-6 (HHV-6) DNA transfected NIH 3T3 transformants

1 reference

12 December 2020

Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer

1 reference

12 December 2020

Induction of major histocompatibility class I antigens by interferons in undifferentiated F9 cells

1 reference

12 December 2020

Murine lymphokine-activated killer (LAK) cells: phenotypic characterization of the precursor and effector cells

1 reference

12 December 2020

Flow cytometric analysis reveals the presence of asialo GM1 on the surface membrane of alloimmune cytotoxic T lymphocytes

1 reference

12 December 2020

Differential effects of recombinant interferons alpha, beta, and gamma on induction of human lymphokine (IL-2)-activated killer activity

1 reference

12 December 2020

Eradication of mouse melanoma by combined treatment with recombinant human interleukin 2 and recombinant murine interferon-gamma

1 reference

12 December 2020

Interleukin-2 activated human killer lymphocytes: lack of involvement of interferon in the development of IL-2-activated killer lymphocytes

1 reference

12 December 2020

In vivo antitumor activity of multiple injections of recombinant interleukin 2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors

1 reference

12 December 2020

Interaction of recombinant interferons with recombinant interleukin-2: differential effects on natural killer cell activity and interleukin-2-activated killer cells

1 reference

12 December 2020

Hyporesponsiveness to augmentation of murine natural killer cell activity in different anatomical compartments by multiple injections of various immunomodulators including recombinant interferons and interleukin 2

1 reference

12 December 2020

Comparative effects of various classes of mouse interferons on macrophage activation for tumor cell killing

1 reference

12 December 2020

Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma.

1 reference

12 December 2020

Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases.

1 reference

12 December 2020

Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor-alpha

1 reference

12 December 2020

Establishment of monoclonal anti-Nk-1.1 antibody.

1 reference

12 December 2020

Phase II trials of recombinant leukocyte A interferon in disseminated malignant melanoma: results in 96 patients.

1 reference

12 December 2020

Inhibition of experimentally-induced murine metastases by recombinant alpha interferon: correlation between the modulatory effect of interferon treatment on natural killer cell activity and inhibition of metastases

1 reference

12 December 2020

In vivo anti-tumor activity of combinations of interferon alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells

1 reference

12 December 2020

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

12 December 2020

Interleukin 4 (B cell stimulatory factor 1) can mediate the induction of lymphokine-activated killer cell activity directed against fresh tumor cells

1 reference

12 December 2020

Recombinant interferon enhances monoclonal antibody-targeting of carcinoma lesions in vivo

1 reference

12 December 2020

Direct antiproliferative effects of recombinant human interferon-alpha B/D hybrids on human tumor cell lines

1 reference

12 December 2020

Reactivity of anti-asialo GM1 serum with tumoricidal and non-tumoricidal mouse macrophages.

1 reference

12 December 2020

Systemic administration of recombinant interleukin 2 stimulates in vivo lymphoid cell proliferation in tissues

1 reference

12 December 2020

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

1 reference

12 December 2020

In vivo administration of interferon alpha and interleukin 2 induces proliferation of lymphoid cells in the organs of mice

1 reference

12 December 2020

Interactive effects of alpha-interferon A/D and interleukin 2 on murine lymphokine-activated killer activity: analysis at the effector and precursor level

1 reference

12 December 2020

Augmentation of human natural cell-mediated cytotoxicity by recombinant human interleukin 2

1 reference

12 December 2020

Partial reversion of the transformed phenotype of murine sarcoma virus-transformed cells in the presence of interferon: a possible mechanism for the anti-tumour effect of interferon.

2 references

12 December 2020

Crossref

https://api.crossref.org/works/10.1111/J.1365-2249.1991.TB05726.X

Interleukin-2 augments natural killer cell activity

6 November 2022

1 reference

12 December 2020

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

1 reference

12 December 2020

Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. I.

1 reference

12 December 2020

Identification of ganglio-N-tetraosylceramide as a new cell surface marker for murine natural killer (NK) cells

1 reference

12 December 2020

Mechanism of the Antitumour Effect of Interferon in Mice

1 reference

12 December 2020

Long term culture of tumour-specific cytotoxic T cells

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1038/268154A0

Quantification of natural cytotoxicity by human lymphocyte subpopulations isolated by density: Heterogeneity of the effector cells

1 reference

https://api.crossref.org/works/10.1111/J.1365-2249.1991.TB05726.X

Synergism between alpha-interferon and interleukin-2-activated killer cells: in vitro studies

6 November 2022

1 reference

https://api.crossref.org/works/10.1111/J.1365-2249.1991.TB05726.X

6 November 2022

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1713814%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1713814

6 November 2022

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1713814%20AND%20SRC:MED&resulttype=core&format=json